Entero Therapeutics Ink LOI To License Data Vault's Clinical Trial Management Platform For GI Disease Trials
Entero Therapeutics Ink LOI To License Data Vault's Clinical Trial Management Platform For GI Disease Trials
Under the terms of the Letter of Intent, Entero Therapeutics, upon execution of a definitive agreement, would receive an exclusive, global license to pilot the technology platform in Entero Therapeutics' clinical trials, and to develop and commercialize Data Vault's QOLPOM and FotoDigm patented pharmaceutical regime compliance software for use in clinical trials with third-parties in the pharma and biotech sectors. In consideration, Entero Therapeutics will issue to Data Vault shares of the Company's convertible preferred stock priced at a premium to the market and single digit revenue sharing royalties on net sales. The Proposed Transaction is expected to close by the end of September, and the entry into definitive documentation will be conditioned upon fulfillment requirements of no less than $500K of strategic investment into Entero Therapeutics (the "Strategic Investment"), with a target of ultimately securing up to $3 million of further strategic investment with Data Vault's assistance. The terms of the Proposed Transaction provide for Data Vault to support the Company's pursuit of the Strategic Investment. The Strategic Investment would provide Entero Therapeutics with access to both capital and technology for a pilot program and the initiation and potential improvement of the Company's future clinical trials.
根據意向書的條款,Entero Therapeutics在執行最終協議後,將獲得全球獨家許可,用於在Entero Therapeutics的臨床試驗中試用該技術平台,並開發和商業化Data Vault的QolPom和FotoDigm專利製藥制度合規軟件,用於與製藥和生物技術領域的第三方進行臨床試驗。作爲對價,Entero Therapeutics將向Data Vault發行該公司可轉換優先股的股票,股票定價高於市場,淨銷售額爲個位數的收益分成特許權使用費。擬議的交易預計將於9月底完成,最終文件的錄入將以滿足對Entero Therapeutics不少於50萬美元的戰略投資(「戰略投資」)的要求爲條件,目標是在Data Vault的協助下最終獲得高達300萬美元的進一步戰略投資。擬議交易的條款規定使用Data Vault來支持公司進行戰略投資。該戰略投資將爲Entero Therapeutics提供資金和技術的機會,用於試點計劃以及公司未來臨床試驗的啓動和潛在改進。